---

A comparative study between ranibizumab and its first biosimilar razumab in terms of efficacy and safety in DME, RVO and wet AMD associated with CNVM

---

Original Article

Author Details : Preethi B*, Shilpa G , Dhwani Anil Shah, Praveen R Murthy

Volume : 7, Issue : 2, Year : 2021

Article Page : 346-351

https://doi.org/10.18231/j.ijceo.2021.068

Suggest article by email

Get Permission

---

Abstract

Purpose: To compare safety and efficacy of intravitreal therapy between anti vascular endothelial growth factor (Anti-VEGF) Ranibizumab and biosimilar Razumab in diabetic macular oedema (DME), wet age related macular degeneration (AMD) with choroidal neovascular membrane (CNVM) and retinal vein occlusion (RVO).
Methods: Prospective comparative study involved 60 eyes of 56 adults, randomized into 2 groups from September 2016 to November 2017. Group 1 (n=30) received Ranibizumab (0.5mg in 0.05ml) and group 2(n=30) Razumab (0.5mg in 0.05ml). Initial loading dose of one injection given to all subjects and a pro re nata schedule followed thereafter. Patients received maximum of 3 injections and were followed up to 12 weeks. Best corrected visual acuity (BCVA) and central foveal thickness (CFT) were considered for the primary outcome and adverse drug reactions (ADR) was considered in the secondary outcome. A p value of less than 0.05 was considered statistically significant.
Results: The 12-week mean BCVA in group 1 was 0.39 (+-0.24); and in group 2 was 0.53 (+-0.37), which had improved significantly from baseline (group 1 p= 0.007, group 2 p <0 p=0.249). p=0.544). p=0.305).> Conclusion: In this study both Ranibizumab and Razumab were safe and efficacious.

Keywords: Biosimilar, Ranibizumab, Choroidal neovascular membrane, Diabetic macular oedema, Retinal vein occlusion.

How to cite : Preethi B, Shilpa G, Shah D A, Murthy P R, A comparative study between ranibizumab and its first biosimilar razumab in terms of efficacy and safety in DME, RVO and wet AMD associated with CNVM. Indian J Clin Exp Ophthalmol 2021;7(2):346-351

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.